From treatments for cancer to stem cell breakthroughs , and 3-D-printed organs scientists are creating new trends that we believed could only be described as science fiction (although we don’t yet have the ability to teleport). Imagine how much smaller the footprint of the environment would be if there was the capability of teleportation. Researchers and do what you can.
Return to the real world and the concept of tangibility.
Many of the biggest innovations in medical research have come from research conducted in the field of biotech.
What is biotech? And why is it attracting billions of dollars of investment?
In this article we’ll try to answer these questions and many more. We’ll look at the biotech industry, its significant technological breakthroughs and the reasons it is attracting huge sums of money, and why it is worth considering biotech companies in your portfolio of investments.
How do you define biotech?
You’ve heard about the phrase. It’s got something related to breakthroughs in medical research. But, biotechnology is more than that.
There are five different branches which modern biotechnology could be classified into:
Human
Environmental
Industrial
Animal
Plant
Each one of these branches contributes in fighting hunger and disease. They aid in sustainable production and can aid in reducing our environmental footprint as well as save energy.
Biotechnological processes are also responsible for the wine and beer that you drink and the bread you consume and the milk that is lactose-free.
Bread and beer apart, biotech has usually linked to researchers and doctors trying to discover and possibly succeed in creating medicines derived from living organisms by with the help of technology.
Simply put, it’s science and technology merged.
In the field of medicine, biotech could be utilized to treat rare and debilitating illnesses and enhance the quality of life. This includes the development of vaccines that combat all kinds of measles, hepatitis Mumps, measles and even certain of the most commonly-spread cancers, including cervical vaccines, such as Merck’s Gardasil(r).
Some of the most important innovations made in biotech include.
Stem cell research
Nerve regeneration
Therapy for cancer that is targeted
Gene editing
Human genomic sequencing
Augmented real-time in surgery
Organs 3D printed
And much more…
Biotech is an important topic
With the many breakthroughs achieved in biotech, it’s not surprising that this field attracts billion-dollar deals as well as large investment.
A biotech company that is successful will see a huge increase in profits and revenue.
Grandview Research reports the global biotechnology market will grow to $2.44 trillion by 2028.
This can be assisted with COVID-19. COVID-19 pandemic.
Pfizer reported revenue of 86% increase in its second quarter 2021. the sale of COVID-19 vaccine wasn’t included in the figures.
Pfizer’s Q3 earnings reported the company’s revenue at $24.1 billion, which is compared to an estimate that was $23.5 billion, and a $22.6 billion, which is the consensus estimate.
The bottom line of the company was $1.34 per share basis and an adjusted basis was up 133% over the previous year.
Whatever you think about the COVID-19 vaccine, vaccinations in general are a significant growth factor for any company. For Pfizer its COVID-19 vaccine, the company made revenue of $13 billion over the first quarter.
In the nine months (ending Sept. 2021) for the vaccine are at over $24 billion. There are forecasts of $36 billion for whole year 2021 and $30 billion by 2022.
Pfizer is among the largest companies worldwide and is an example of how much money biotech firms can make by proving its products. If you’re a small business the big pharmaceutical companies could call you to buy you.
The $2 billion investment by Blackstone of $2 billion in Alnylam Pharmaceuticals (NASDAQ:ALNY) in April 2020 was one the largest private financings of a biotech firm.
The numbers are an enormous boon for the companies involved and their investors.
Notable was also AstraZeneca’s $39 billion acquisition of Alexion Pharmaceutical and Gilead’s $21 billion purchase of Immunomedics.
In 2020 most of the deals witnessed approximately $97 billion worth biopharma assets being transferred. This was less than more than $207 billion that was recorded in 2019, however, that is because of the pandemic, and the fact that the wheel is now getting ready to spin.
The most important biotech drug
Statista states the fact that AbbieVie and Roche hold the largest biotechnology products currently available. Roche is the largest biotech firm globally, with its prescription drug biotech revenue expected to be over $US48 billion by 2028.
Roche’s Avastin drug was responsible for about $US7.1 billion in 2019 , before the pandemic erupted. Avastin helps to stop the growth of blood vessels for treating certain kinds of cancer. Roche’s Rituxan is used to treat conditions that cause autoimmune disease and other forms of cancer. It generated $4.5 billion last year.
The AbbiVie’s Humira is an antirheumatic medicine. The drug treats severe to moderate rheumatoid joint in adults. It generated $US19.8 billion in 2020.
What is an “blockbuster?
It’s not a redundant video store and neither is it an Marvel film or any other movie starring Tom Cruise.
A biotech blockbuster is a medicine that earns more than one billion dollars of sales.
The drugs comprise Lipitor as well as Zoloft and typically address common medical issues such as high cholesterol high blood pressure, diabetes asthma, cancer and high blood pressure.
Every biotech is eager to develop blockbuster drugs , and every investor is pushing them to take this step.
A blockbuster drug can create an biotech company, however for investors there aren’t any big dollar indicators. There are risks to investing in biotechnology, and you should be on watch when you are deciding on which stocks you should invest your money in.
The advantages for investing in biotech
A thorough and diligent approach is essential to the success of your biotech investment.
A rigorous level of examination is necessary to distinguish what is wheat and what’s chaff.
A biotech-related stock – an investment that represents a business in the biotech industry – is often the most difficult stock to choose effectively.
Biotech investment comes with risky investments. While the investment in companies that specialize in biotech could result in massive profits There exist pros as well as cons that every investor must be aware of.
Let’s begin with the pros.
Products that are required
Biotech companies have the ambition to develop new medical treatments and technological breakthroughs that will transform the world: end the spread of disease and end hunger in the world …
Anything that claims to achieve that goal and has the right people, finances, and even a product idea is one to keep an eye on.
The products must satisfy a community need. If they don’t you don’t need it, then stop looking.
A growing market
Although the figures vary from research institutes biotech is an expanding market. Global Market Insights predicts the market will increase to $950 billion by 2027.
This is due to an increase in chronic illnesses and the associated healthcare costs.
A business that helps reduce pain or illness through the production of drugs will flourish. In addition an organization that has cutting-edge technology products can reduce costs and lessen health care burden.
The companies that are in them could increase rapidly in terms of value.
Fior Markets predicts the biotech sector to grow at an annual compound rise of 7.02 percent between 2020 and 2027 , and will reach US$833.34 billion at the end of the forecast time.
Grandview Research estimates the global biotechnology market could be $2.44 trillion.
ESG
Biotech companies provide investors with the opportunity to invest in socially responsible companies.
They are generally able to meet investors’ demands regarding environmental or corporate governance, as well as ethical aspects, in addition to financial returns.
The ethical investors invest on their own values. The majority of biotech companies are working towards creating a positive impact on the society and the natural planet.
Portfolio with a balanced balance
Biotech stocks can be a good option to ensure an appropriate portfolio.
Investors can not only back innovative technology, but they can also diversify their portfolios by incorporating a an array of high-risk, and high-reward investments like emerging biotech small caps such as Imugene Ltd (ASX:IMU, OTC: IUGNF), Noxopharm Ltd (ASX:NOX) (brain cancer), Chimeric Therapeutics Ltd (ASX:CHM) (cell therapy), Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) (bone Marrow and treatments for liver cancer), Arovella Therapeutics Ltd (iNKT cell therapy platform) and Kazia Therapeutics Ltd (ASX:KZA, KZIA on NASDAQ) (newly discovered glioblastoma) and more well-established, profitable companies like Roche.
Earn money
A stake in biotech stocks can be profitable. If you’re at the top of the line after the launch of a successful product an innovative treatment, it is normal to witness a share price increase.
If it’s an equities company The sky is the limit.
If it’s Pfizer during a pandemic there’s a lot of gains to be achieved.
However, caution is necessary. It is not likely that every company will be able to discover a breakthrough or an action-packed blockbuster. As we’ve stated that due diligence is essential and professional advice is recommended prior to making a decision for a biotech stock.
The pros and cons to investing your money in biotechnology
Commercial failures
A biotech company might produce what appears to be the most effective product available however this doesn’t mean that it will be an economic success.
It requires thousands of dollars make an item and should it fail to make profits, you’re likely to see your reduction in the price of shares.
Clinical failures
Before even reaching the stage of commercialization an item must undergo several trials.
Many times, those tests are unsuccessful and then it’s again back to the drawing board and millions of dollars being wasted.
If you are considering investing in a biotech company be sure to check the stage they’re at.
The first stage is the discovery and research phase , which is the most risky. There isn’t a product.
The Stage 2 stage is considered preclinical, and as such, it is dangerous. The need for capital is a requirement and regulatory hurdles have to be overcome.
Stage 3 is the stage where companies at the clinical stage have developed their product and got it cleared for human clinical trials. This stage can bring short-term benefits, but it is also rife with risks.
Any stage later is more secure. Biotech companies that are in late clinical stage, the point of bringing new medical devices to commercialization and commercial-stage companies are worth watching.
There is no money
In some cases, early-stage biotech firms are unable to find the funds they need to conduct trials. Avoid those who are who are struggling to find capital.
Be sure to weigh the risk against reward prior to making a decision to invest
There are fantastic rewards as well as great risk associated with investing in biotech.
Do your homework.
The more well-prepared you are, and the more information you know the better choice you’ll be able to make.
Simply put, be vigilant and know your risk tolerance.
